Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
Jason J. Luke(University of Chicago), Georgina V. Long(The University of Sydney), John M. Kirkwood(UPMC Hillman Cancer Center), Luis de la Cruz‐Merino, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Federica De Galitiis(Istituto Dermopatico dell'Immacolata), Alexander M.M. Eggermont(University Medical Center Utrecht), Francesco Spagnolo(Martin University), Jean‐Jacques Grob(Aix-Marseille Université), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Larry Wu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Matteo S. Carlino(The University of Sydney), Caroline Robert(Institut Gustave Roussy), Jacek Mackiewicz(Poznan University of Medical Sciences), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Muhammad Adnan Khattak(Edith Cowan University), Mizuho Fukunaga‐Kalabis(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 18
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k